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Physiological as well as pathological blood vessel formation are fundamentally dependent on cell-matrix interaction. Integrins,
a family of major cell adhesion receptors, play a pivotal role in development, maintenance, and remodeling of the vasculature.
Cell migration, invasion, and remodeling of the extracellular matrix (ECM) are integrin-regulated processes, and the expression
of certain integrins also correlates with tumor progression. Recent advances in the understanding of how integrins are involved
in the regulation of blood vessel formation and remodeling during tumor progression are highlighted. The increasing knowledge
of integrin function at the molecular level, together with the growing repertoire of integrin inhibitors which allow their selective
pharmacological manipulation, makes integrins suited as potential diagnostic markers and therapeutic targets.
1.Introduction
Invasive cancer is among the leading causes of death world-
wide, and rates are still increasing, due to ageing and
changes in lifestyle [1]. Cancer is a collective term for many
diseases, rather than a single disease, with the common
characteristic that tissue growth goes haywire [2]. Patients
whohaveundergonecancertreatmentshowanincreasedrisk
of developing a second tumor, mainly due to the same risk
factors that were responsible for the ﬁrst tumor but also in
part due to the treatment of the ﬁrst tumor with mutagenic
chemotherapeutics or radiation [3]. Therefore, new strate-
gies for cancer treatment with as little as possible adverse
side eﬀects are needed that eﬀectively eradicate the primary
tumor and also do not increase the risk of recurrence.
A tumor initially grows without any connection to the
vasculature until it reaches a critical size of about two mm
in diameter. Then it remains in a dormant state, in which
proliferation and apoptosis due to lack of oxygen, are in a
dynamicequilibriumunlessitdevelopsinawell-vascularized
region or is able to recruit its own vasculature. Hanahan
and Weinberg have proposed six hallmarks of cancer, one of
them being the induction of angiogenesis [4, 5]. For further
growth, the tumor needs to hook up to the vascular system
by forming neovessels.
During tumor progression, an angiogenic switch is acti-
vated causing a continuous neovessel formation emanating
from the normally quiescent vasculature, which sustains
tumor growth [6]. This process called tumor angiogenesis
is a collective term that is generally used for all types of
tumor neovascularization. In addition to vessel co-option
andtoendothelial cell(EC)sprouting,tumorvesselscanalso
develop by intussusceptive or glomerular angiogenesis, or,
in a way of vascular mimicry, even tumor cells themselves
can form vessel-like hollow structures. These types of vessel
formation can occur in parallel, and also gradual transitions
are possible. Vessel formation by the latter types requires less
energythansproutingangiogenesis,isthuscarriedoutfaster,
and usually can be observed in, for example, gliosarcoma
multiforme, melanoma, and breast and colon cancer [7].
For neovessel formation, ECs need to migrate into a pre-
viously avascular region and to extensively remodel the
extracellular matrix (ECM). In this process, integrins, which
are cell adhesion receptors for various ECM proteins
and immunoglobulin superfamily molecules, are the most
important matrix receptors [8, 9]. Therefore, integrins are2 Journal of Oncology
appealing targets for cancer therapy using a variety of inte-
grin-speciﬁc antagonists, ranging from endogenous antago-
nists over humanized or chimeric antibodies to peptides and
small nonpeptidic compounds [10–12].
In this paper, based on the general assembly of blood
vessels, the speciﬁc organization of tumor vasculature will be
described,aswellasthedynamicsequenceofeventsbywhich
atumorgainsaccesstothebody’svasculature.Inthiscontext,
theroleofintegrinsandpossibilitiesoftheirpharmacological
manipulation are explored.
2.TheStaticPicture:The ExtracellularMatrix
ofBloodVessels
The tissue’s ECM is a structure-shaping molecular scaﬀold
and also a repository for cytokines and other growth factors
[13]. Cells embedded in this matrix need to be supplied
with oxygen and nutrients, signaling molecules need to be
received and emitted, and metabolic waste products need
to be disposed of. These tasks are optimally fulﬁlled by the
cardiovascularsystemwithitsintricateanddynamicnetwork
of blood vessels. Depending on their functions, diﬀerent
typesofbloodvesselsshowspecialhistologicalandmolecular
adaptations. The heart, as a double-acting pump, drives
the blood circulation within the vasculature via the aorta
through arteries and arterioles into capillaries, from where
the blood ﬂows back through venules and veins. Due to
the prevailing pressure conditions, the body ﬂuid is forced
through the vessel wall to form the lymph, which then is
drained by lymph vessels back to the blood circulation.
Additionally, the vasculature serves as “highway” system
for leukocytes to patrol the body during immunological
surveillance and to quickly reach sites of inﬂammation. The
vascular wall is capable of self-sealing upon smaller injuries,
and leukocytes are able to penetrate the blood vessel wall
in a complex interplay without any obvious vessel leakage.
Pathologically, tumor cells capitalize the blood vessel system
to disseminate from a primary tumor and to colonize distant
organs where they develop metastases.
2.1. General Organization of the Vessel Wall. Histologically,
the walls of blood vessels comprise three concentric layers,
that is, tunica intima, tunica media, and tunica adventitia
[14], which are separated by two sheet-like structures of
ECM proteins. The membrana limitans interna and externa
establish a border between tunica media and tunica interna
and adventitia, respectively. These ECM sheaths tightly
connect the cell layers of the vessel wall to form a functional
unit, which becomes evident when too weak cell-matrix
interactions lead to life-threatening aneurysms.
The tunica intima comprises a single layer of squamous
ECs and lines the inner surface of all blood vessels. The
tunica media, which is usually the thickest layer in arteries,
is composed of mural cells, which are smooth muscle cells
in larger blood vessels and pericytes in capillaries. The
tunica adventitia ﬁnally interconnects the blood vessel with
the surrounding connective tissue, and it is usually most
prominent in veins.
In diﬀerent vessel types, that is, arteries, arterioles, cap-
illaries, venules, and veins, this general blueprint is mod-
iﬁed corresponding to the respective functional require-
ments. For example, endothelia, which are continuous in
most instances, can become fenestrated, as in exocrine or
endocrine gland tissues, or even discontinuous, as in liver,
spleen, or bone marrow, in order to facilitate the exchange
of hormones or metabolites. Elastic and muscular arteries
illustrate other examples for a modiﬁcation of this general
blueprint. In order to even the pulsatile blood ﬂow coming
from the heart, the proteins elastin and ﬁbrillin are abundant
in the tunica media ECM of elastic arteries, which is the
direct cause for the vessel wall’s elastic properties. Muscular
arteries possess numerous concentric sheaths of smooth
muscle cells. By means of vasoconstriction and vasodilation,
they can distribute and direct the blood to diﬀerent organs.
2.2. Extracellular Matrix in the Vessel Wall. The ECM of
blood vessels together with their resident cells contributes to
essentiallyallphysiologicalfunctionsofbloodvesselsandhas
been reviewed recently [15].
The subendothelial basement membrane (BM) com-
partmentalizes the vessel’s single-layered endothelium from
the vascular connective tissue. The molecular architecture
of BMs has recently been reviewed [16–18]. Fibronectin,
incorporated between endothelial and perivascular cells, is
essential for blood vessel morphogenesis [19]. The presence
of von Willebrand factor (vWF) is characteristic for the
subendothelial BM, where also other BM proteins, such as
the network-forming collagens IV and XVIII can be found,
together with laminins, nidogens, and perlecan. Thirteen
diﬀerent collagens are present in the vascular wall [20, 21].
The network-forming collagen IV [22] plays a key role for
the mechanical stability of the BM [23], which, especially in
arterial regions of the circulatory system, has to withstand a
considerable blood pressure.
In the tunica media of elastic and muscular arteries,
covalently crosslinked supramolecular aggregates of elastin
form concentric lamellae and ﬁbers in a proportion of up
to 50% of the vessel’s dry weight and confer resilience
to pulsatile blood ﬂow [24–26]. Regions of the ECM that
consist mostly of elastin are conﬁned by EMILINs, that is,
homotrimeric elastin microﬁbril interphase-located proteins
[27]. Anchored to microﬁbrillar bridges of ﬁbrillin-1 and
ﬁbulin-5 between these concentric elastin lamellae, vascular
smooth muscle cells (VSMCs) are sandwiched in a ﬁshbone-
like pattern and thus can eﬀectively regulate the vessel’s
caliber [25, 28–31]. Dependent on the vessel type, distinct
ﬁbulins are involved in the assembly of the ECM. While
ﬁbulin-1 is widespread and occurs in the BMs of all blood
vessels, heart valves and septa, ﬁbulin-3, and ﬁbulin-4 occur
in the walls of capillaries and larger blood vessels [32]. The
innermost and outermost elastic lamellae are referred to as
membrana limitans interna and membrana limitans externa,
respectively. Between the elastic lamellae, type I and III
collagens are deposited that bear tensile forces exerted on
the vessels and limit their elastic dilatability. In contrast, in
the interstitial connective tissue between the subendothelial
membrane and the membrana limitans interna, type VI andJournal of Oncology 3
type VIII collagens are found [21, 33]. The connection of
the membrana limitans interna to the subendothelial BM by
type XVIII collagen is assumed [34]. Also type XVI collagen,
which is produced by VSMCs and found close to both
elastic microﬁbrils and ﬁbrillar type I and type III collagens,
may contribute to the connection between the elastic and
collagenous phases of the ECM [35, 36], especially, as type
XVI collagen contains a binding site for the major collagen
receptor on VSMCs, integrin α1β1[ 37, 38].
The ECM of the tunica media is synthesized by VSMCs,
whichareallencapsulatedbyan(incomplete)BMcontaining
the usual BM proteins, type IV collagen and laminins
[33, 39]. Depending on microenvironmental cues, VSMCs
can reversibly acquire distinct phenotypes, which can be
characterized as either (i) contractile and diﬀerentiated or
(ii) secretory, migratory, and less diﬀerentiated [37, 39].
Under physiological conditions, the contractile phenotype
prevails, at which the VSMCs transduce forces on the
pericellular matrix especially by the collagen-binding inte-
grin α1β1, by the laminin-binding integrin α7β1a n db y
dystroglycan [37]. In contrast, in the secretory, proliferatory,
and migratory phenotype, the integrin equipment of the
VSMCs predominantly consists of the ﬁbronectin receptor,
α5β1, and the integrins α4β1a n dα9β1. Consistently, in the
proximityofsecretoryVSMCs,theﬁbronectinsplicevariants
V(IIICS)andEIIIAwithbinding sitesfortheintegrins α4β1,
α5β1, and α9β1 are abundant [39]. In capillaries, scattered
pericytes, each encapsulated by an own BM, stabilize the
endothelium and its subendothelial BM [40–42].
The ﬁbroelastic connective tissue of the tunica adventitia
connects the blood vessel with the perivascular connective
tissue.Itisrichinversican,aglycoprotein,whichcaninteract
withﬁbrillin-1[43],ﬁbulin-1[44],andﬁbulin-2[45],aswell
as with other ECM molecules.
2.3. Receptors for ECM Molecules. To interact with their
microenvironment and to spatiotemporally regulate their
diﬀerentiation state, morphology, metabolism, and survival,
cells are equipped with a variety of receptors for all the
ECM molecules [13]. Integrins are the largest family of these
receptors, and they mediate adhesion to collagens, laminins,
and ﬁbronectin. In addition, there are other receptors and
coreceptors, such as the syndecans [46].
Binding to a wide variety of diﬀerent ECM molecules
and transmitting signals bi-directionally in an outside-in
and inside-out manner, integrins constitute functional hubs,
which, according to an interesting concept in network theory
and systems biology, integrate networks of angiogenic sig-
naling cues that orchestrate the behavior of ECs and VSMCs
during angiogenesis [47, 48]. Thus, therapeutically targeting
integrins as the operationally important circuit-integrating
hubs rather than single pathways of the complex system may
result in a more pronounced inhibition of angiogenesis [47].
ECs express the vitronectin receptors αvβ3a n dαvβ5;
moreover, on ECs and pericytes the following integrins are
expressed: the collagen receptors α1β1a n dα2β1, the laminin
receptors α3β1, α3β6, and α6β4, the osteopontin receptor
α9β1, and the ﬁbronectin receptors α4β1a n dα5β1[ 49].
Pericytes additionally express the laminin receptor α7β1, and
the osteopontin receptor α8β1, and integrin αvβ3 is also
expressed on glial cells [49].
As EC-derived tumors, angiosarcomas express the inte-
grins α1β1, α2β1,α3β1,α5β1, and α6β1, and in benign and
malignant mesenchymal tumors as well as in the desmoplas-
ticstromaofcarcinomas,integrinsα1β1andα5β1ar ewid el y
distributed [50]. Integrins α1β1a n dα2β1 bind to the same
ligand in the ECM and are VEGF-dependently upregulated
on migrating ECs, and antagonists against both integrins
inhibit VEGF-mediated angiogenesis without aﬀecting the
existing vasculature [51, 52]. Therefore, and against the
background of gene ablation studies, they are believed to dif-
ferentially regulate angiogenesis [49]. Important coreceptors
for integrin α2β1 are the syndecans-1 and -4, which weaken
theinvasivenessoftumorcellsintoacollagenousmatrix[53].
Cells bind to ﬁbronectin and vitronectin preferentially
via the RGD-dependent integrins αvβ3a n dα5β1[ 54].
Fibronectin can also be bound by the leukocyte-speciﬁc
integrins α4β1a n dα4β7[ 55]. Cell-ﬁbronectin interactions
are modulated by proteoglycans, glycoproteins of the ECM,
and the coreceptors syndecans [56].
Integrin αvβ3 was identiﬁed as a marker for angiogenic
vascular tissue [57]. In contrast to quiescent ECs, integrin
αvβ3 is highly expressed on activated ECs during tumor
a n g i o g e n e s i s ,a sw e l la so ns o m et u m o rc e l l s[ 58, 59]. In the
tumor microenvironment, angiogenic ECs can interact due
to their increased levels of the integrins αvβ3a n dαvβ5
with provisional matrix proteins, such as vitronectin, ﬁb-
rinogen, vWF, osteopontin, and ﬁbronectin. Also, partially
proteolyzed collagen in the tumor exposes RGD sites and is
a further ligand for integrin αvβ3[ 60]. Thus, the ECM of
the tumor microenvironment both provides survival signals
and facilitates invasion. Integrin-αvβ3-mediated adhesion
to platelets protects malignant cells from clearance through
the immune system, and moreover, αvβ3 integrin also helps
tumorcellstoadheretothevesselendotheliumandtospread
into adjacent tissues [61].
The pharmacological inhibition of integrin-αvβ3-
mediated cell-matrix interaction impedes tumor angiog-
enesis and growth [62], as does a replacement of the β3
subunit with a mutated nonphosphorylatable subunit in a
murine model [63], which provides evidence for a proan-
giogenic role of integrin αvβ3, in contrast to integrin αvβ5,
which does not seem to play an essential role in angiogenesis
[64]. Interestingly, the analysis of αv-knock-out mice
revealed that, despite being embryonic or perinatally lethal,
the vascular endothelium was not impaired in the absence
of the αv subunit, whereas the primary cause of death was
brain hemorrhage [65–67]. Also endothelial Tie-2-speciﬁc
knockout of the αv subunit did not result in any vascular
or angiogenesis defect [67]. Moreover, in an integrin
subunit β3- and also β5-deﬁcient mouse model, pathologic
angiogenesis and tumor growth are increased [68]. A
possible cause for these seemingly contradictory phenomena
could be a relief of a transdominant inhibition by αvβ3o n
other integrins or other molecules, which would enhance
their proangiogenic function [69, 70]. Likewise, there could
be a compensatory role of other integrins with overlapping
function [49]. Moreover, inhibition could also stabilize the4 Journal of Oncology
integrin αvβ3 in its unligated conformation and thus induce
apoptosis by triggering an integrin-mediated death program
[71].
Integrin αvβ8i si m p o r t a n tf o rv a s c u l a rd e v e l o p m e n ti n
the embryonic brain and in the yolk sac [72]. It is expressed
on astrocytes but not on ECs or pericytes, nevertheless plays
an important role in angiogenesis, as it binds in addition to
several ECM proteins also to the latency-associated peptide
(LAP) of TGFβ1, which in cooperation with the membrane-
type metalloproteinase MT1-MMP/MMP14 results in acti-
vation of TGFβ and triggering of its downstream signal
cascades [73–75].
Collagen IV, an essential component of BMs, is bound
by integrin α1β1 ,w h i c hi se x p r e s s e do nm e s e n c h y m a lc e l l s
and can also bind to other collagens [76, 77]. Further
collagen-binding integrins are α2β1, the main receptor for
ﬁbrillar collagens, which is expressed on epithelial and some
mesenchymal cells as well as on thrombocytes [78], α10β1i n
cartilage [79], and α11β1, a key receptor for ﬁbrillar collagen
onﬁbroblasts[80].Theintegrinsα1β1andα2β1ar ein v ol v ed
in the regulation of collagen and MMP synthesis and thus
of special importance for ECM turnover [81–83]. Discoidin
domain receptors DDR1 on epithelial cells and DDR2 on
mesenchymal cells are further collagen receptors with tyro-
sine kinase function and are relevant for cancer [84].
Other collagen receptors are glycoprotein GPIV on platelets
[85],theleukocyte-associatedimmunoglobulin-likereceptor
LAIR-1/CD305 [86], and the urokinase-type plasmino-
gen activator receptor-associated protein uPARAP/Endo180,
whichisinvolvedinmatrixturnoverduringmalignancy[87].
Laminin, as a further integral component of BMs, is
bound by the integrins α3β1, α6β1, α6β4, and α7β1[ 88–
91] and also by α-dystroglycan [92, 93] and by the 67kDa
laminin receptor 67LR [94]. 67LR is increased in various
tumors and correlates with their metastatic potential [95,
96]. The diﬀerent laminin receptors may also act coopera-
tively in laminin binding, for example, laminin-binding β1
integrins and 67LR [97] or integrin α6β4 and syndecan 1
[98].
Integrin α3β1, which in the vascular wall binds to lam-
inins-411 (laminin 8) and-511 (laminin 10), thrombospon-
din (TSP), TIMP2, tetraspanin CD151, and to the C-termi-
nal domain of the collagen IV α3 chain, is controversially
ascribed either a positive or a negative role in angiogenesis
(cf. [99]).
There is controversy whether the hemidesmosomal inte-
grinα6β4,whichisexpressedonasubsetofECs[100]andon
tumor ECs [101], aggravates pathological angiogenesis [101]
or whether it is a negative regulator of angiogenesis that is
downregulated at its onset [102].
Thus, many molecules of the ECM scaﬀold, for example,
laminins, collagens, ﬁbronectin, and vitronectin, are ligands
forintegrinsthatlinkthecell’scytoskeletontotheECM.Loss
of this matrix-integrin contact triggers apoptotic cell death
[103]. Picking up signals from the cell’s microenvironment,
integrins functionally sense, interpret, and distribute infor-
mation, which allows the cell to modulate its proliferation,
diﬀerentiation, migration, and shape [104]. The modulatory
and regulating function of integrins is emphasized by direct
interaction with a multitude of proteins, such as MMPs,
uPA/uPAR, tissue inhibitor of matrixmetalloproteinase-2
(TIMP-2), vWF, TSP-1, osteopontin, syndecan-1, insulin-
receptor substrate-1 (IRS-1), cytohesin-1, integrin cytoplas-
mic domain-associated protein-1 (ICAP-1), integrin-linked
kinase (ILK), calcium- and integrin-binding protein (CIB),
β3-endotoxin, talin, actinin, tensin, nischarin, and the Ras-
related protein Rab 25 [9].
The subendothelial BM of the tunica intima serves as
a mechanical support to which ECs are anchored by vari-
ous adhesion molecules, especially integrins [46, 105–108].
Additionally, the subendothelial BM provides microenviron-
mental information that regulate the metabolic activity of
attached ECs, such as their production of leukocyte adhesion
molecules [107] or antithrombotic prostacyclins [109], as
well as other properties, for example, the tightness of inter-
cellular contacts [108]. Therefore, angiogenesis is regulated
not least by integrins which are adhesion receptors for
matricellular proteins, ECM proteins, and immunoglobulin
superfamily molecules, on nearly all cells including ECs
[8, 58].
In addition to their mechanical function [110], integrins
also assist growth factor receptors and play important roles
insignalingprocesses,inparticularassolublegrowthfactors,
and other signaling molecules are bound by integrins as well
[111]. For example, the proangiogenic VEGF-A165 is bound
by integrins αvβ3a n da 3 β1[ 112] and also by the tenascin-
C- and osteopontin-receptor integrin α9β1[ 113]. The latter
integrin, furthermore, binds the lymphangiogenic growth
factors VEGF-C and VEGF-D [114]. Angiopoietins-1 and
-2 are bound by integrin α5β1[ 115]. Integrin α6β1i sa
receptor for the proangiogenic CCN-family member CYR61,
and is involved in in vivo in tube formation [116, 117]. The
ﬁbronectin receptor integrin αvβ3, which is the best-studied
integrininrelationtoangiogenesisandisupregulatedduring
wound healing and retinal vascularization and especially on
tumor blood vessels, also binds to ﬁbroblast growth factor
FGF-1 [118]. Semaphorin 7A binding is also reported for the
collagen receptor integrin α1β1[ 119].
Stimulated by PDGF, vascular smooth muscle cells
express the laminin receptor integrin α7β1, which plays an
important role in recruitment and diﬀerentiation of VSMCs
[120, 121].
Integrin α9β1 is not only involved in lymphangiogenesis
[114] but also plays a role in EC adhesion [122]. While
binding of TSP-1 to integrin α9β1 promotes angiogenesis
[123], VEGF-A is another ligand of integrin α9β1[ 113].
2.4. Vascular-Relevant Integrin-Deﬁcient Mouse Models. The
crucial involvement of integrins in EC biology has been
elucidatedsubstantiallybytheexaminationofgeneticknock-
out studies [124]. By ablation of the respective genes, the
EC integrins α1β1, α2β1, α4β1, α5β1, α6β1, α6β4, α9β1,
αvβ3, and αvβ5 and also the VSMC integrin α7β1 and the
glial cell integrin αvβ8h a v eb e e ni m p l i c a t e di nr e g u l a t i o n
of cell growth, survival, and migration during angiogenesis
(for recent reviews of the ﬁndings from knock-out mice cf.
[8, 10]). However, due to redundancy and compensatoryJournal of Oncology 5
mechanisms, the interpretation of knock-out results is often
diﬃcult.
Itgb1−/− mice die at E5.5 before they start to develop
their vasculature [125, 126]. Mice with a conditional knock-
out in Tie-2-positive ECs survive until E9.5–E10.5, and
they are capable of vasculogenesis, but their angiogenesis is
disturbed showing defects in sprouting and branching [127–
129]. Another endothelial-speciﬁc knockout of the integrin
β1 subunit is mediated via VE-cadherin-Cre recombinase
and becomes manifest later in embryogenesis resulting in
lethality between E13.5 and E17.5 [130]. In this mouse
model, loss of β1 integrin leads to a decreased expression
of the cell polarity gene PAR3 and thus to disruption of EC
polarity and lumen formation [130].
Itga1−/− mice, deﬁcient for the collagen-binding inte-
grin α1β1, show a normal vascular development and a
reduced tumor angiogenesis in adulthood, which has been
attributed to increased MMP activity [131], while α2β1-
deﬁcient Itga2−/− mice show an enhanced tumor angio-
genesis in adulthood, but an otherwise normal vascular
development [131, 132], and integrin α2β1i si n v o l v e di n
the PlGF-dependent regulation of VEGFR-1 [132]. Although
integrin α1β1a n dα2β1 bind to the same ligand in the
ECM, their diﬀerential knockout results in opposing eﬀects
on angiogenesis, suggesting a regulatory role for this pair of
integrins.
Da Silva and coworkers generated EC-speciﬁc condi-
tional α3 integrin knock-out mice and showed that these
mice, in contrast to a global ablation, are viable and fertile
but display enhanced tumor growth, elevated hypoxia-
induced retinal angiogenesis and tumor angiogenesis, and
increased VEGF-mediated neovascularization [99]. The
authors also could show that α3β1 is a positive regulator of
EC-derived VEGF, which again represses VEGFR2 expres-
sion. Their data demonstrated that endothelial α3β1n e g a -
tively regulates pathological angiogenesis and implicated an
unexpected role for low levels of EC-derived VEGF as an
activator of neovascularization.
Itga4−/− mice, deﬁcient for ﬁbronectin- and VCAM1-
binding integrin α4β1, are embryonic lethal with 50% dying
at E9.5–10.5 due to failure of chorion-allantois fusion and
50% dying at E11.5 due to cardiovascular defects [55].
Mice, which by ablation of Itga5 are deﬁcient for the
ﬁbronectin receptor integrin α5β1, show normal vasculo-
genesis but no angiogenesis, which results in embryonic
lethality at E10-11 due to defects in posterior somites,
yolk sac, and embryonic vessels [133, 134]. This demon-
strates the requirement of the integrin α5 subunit during
embryonic development of early blood vessels and other
tissues.Accordingly,integrinα5β1,whichispoorlyexpressed
on normal quiescent ECs, is markedly upregulated during
tumor angiogenesis [135].
Among the laminin-binding integrins, integrin α6i sn o t
essentially required for vascular development, although α6-
deﬁciency is lethal with skin blistering defects resembling
epidermolysis bullosa [136]. In line with the α6 knock-
out mice, Itgb4−/− mice, lacking a functional laminin-
binding integrin α6β4 by deletion of its signaling domain,
show normal vascular development, although with reduced
angiogenesis [101], but die of severe skin defects [100]. In
neovascularization, the endothelial expression of integrin
α6β1 is downregulated [102]. While it is not required for EC
proliferation and survival, it promotes tumor angiogenesis
[101]. In contrast, genetic ablation of α7β1, which is
expressed on VSMCs but not on ECs, leads to incomplete
cerebral vascularization and hemorrhage and also to pla-
cental vascular defects, which results in partial embryonic
lethality and demonstrates that integrin α7β1i si m p o r t a n t
for recruitment and survival of VSMCs [121, 137].
Deletion of Itga8 resulting in lack of integrin α8β1,
a receptor for ﬁbronectin and tenascin, results in partial
embryonic lethality, but no defects in vascular development
(M¨ uller and Reichardt, cited in [138]).
Itga9−/− mice lacking integrin α9β1, which is the
receptor for tenascin-C, osteopontin, VCAM-1, and also for
VEGF-A, -C, and -D [113, 114], have defects in large lym-
phatic vessels and die postnatally at P8-12 from a bilateral
chylothorax [139].
Ablation of Itgav, resulting in simultaneous loss of the
two integrins αvβ5, a receptor for vitronectin, osteopontin,
and Del-1 (developmental locus 1), and αvβ3, a recep-
tor for a variety of ECM proteins, such as ﬁbronectin,
vitronectin, laminins, ﬁbrinogen, ﬁbrin, TSP, tenascin-C,
vWF, denatured collagen, osteopontin, MMP-2, Del-1, bone
sialoprotein, FGF-2, thrombin, and CCN1 (cystein-rich
protein 61), leads to 80% embryonic lethality at E9.5, and
the other 20% die at P0 with brain hemorrhage [65]. On
the other hand, Itgb3−/− mice, which are just integrin-αvβ3
deﬁcient, show 50% embryonic and early postnatal lethality
and an enhanced angiogenesis in surviving adult animals,
indicating that this integrin is not strictly required for vascu-
lar development [140]. Surprisingly, animals with an intact
but nonfunctional β3 integrin subunit develop normally but
show defects in angiogenesis in adulthood [63]. In contrast,
Itgb5−/− animals lacking integrin αvβ5d e v e l o pn o r m a l l y
and angiogenesis is not signiﬁcantly aﬀected, indicating that
thisintegrinisnotmandatoryforvasculardevelopment[64].
Integrins β3a n dβ5 doubly deﬁcient mice show enhanced
tumor growth and angiogenesis. This strongly suggests that
these integrins are not required for vascular development or
for pathological angiogenesis, pointing out that the mode of
actionofαvβ3antagonistsandantiangiogenictherapeuticsis
still insuﬃciently understood [68]. Ablation of Itgb8 leads to
the loss of integrin αvβ8 on glial cells and thus to disrupted
blood vessel formation in the brain, thereby demonstrating
that this integrin is mandatory for brain’s blood vessel
development [72]. Moreover, the phenotype of β8-deﬁcient
mice resembles that of αv-deﬁcient mice, which provides
evidence that most defects in αv-deﬁcient mice are due to
the loss of integrin αvβ8[ 72].
2.5. Integrin Structure. The family of integrins contains 24
structurally related N-glycosylated heterodimeric proteins
assembled noncovalently from 18 α-subunits and eight
β-subunits. Each subunit comprises a large extracellular
domain, a single transmembrane domain, and with the
exception of the β4 integrin subunit, a short noncatalytic
cytoplasmic tail [141]. Integrins are of special importance as6 Journal of Oncology
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Figure 1: Integrin activation. Integrins are a family of heterodimeric transmembrane adhesion receptors that bidirectionally relay signals
with the extracellular matrix (ECM) and also with other cells. When activated, a conformational change increases the aﬃnity, and clustering
increases the avidity towards the ligand. (1) By inside-out signaling, integrins can reversibly undergo a conformational change from a bent
inactive to an upright activated conformation with intermediate ligand aﬃnity, at which the cytoplasmic domains are still close together.
(2) Upon ligand binding, the integrin adopts a high-aﬃnity conformation with a concomitant parting of the legs and a separation of
the cytosolic α-a n dβ-tails that unlocks docking sites for cytosolic molecules. (3) Clustering of ligand-occupied and activated integrins
establishes a mechanical link between ECM and cytoskeleton and leads to the recruitment of scaﬀolding molecules and kinases. (4) The
assembly of focal adhesions triggers intracellular signaling cascades. Details can be found in the text.
they mediate cell matrix crosstalk via both outside-in and
inside-out signaling [54, 142]. Moreover, the 24 diﬀerent
integrins possess promiscuous and redundant ligand speci-
ﬁcities,whichisofimportancewhendistinctsignalsaretobe
transduced or when in a particular context a deﬁned cellular
response is elicited, as is discussed by R¨ uegg and Alghisi [11].
Integrin structure and function have been studied in
detail at the molecular level [143, 144]. The extracellular
headpiece is formed by a disk-like propeller domain of the
α subunit and globular domains of the β subunit [145, 146].
The joint globular head harbors the ligand-binding site [146,
147]. The crystal structure of the integrin-αvβ3-binding site
with an inserted RGD ligand [148] helped to map functional
amino acid residues on other integrins [149]. Recently,
the binding pocket of integrin α5β1h a sb e e nm a p p e db y
swapping regions of zebraﬁsh and human α5 subunit in a
gain-of-function approach [150].
2.6.IntegrinSignaling. Dependingontheiractivity,integrins
adopt distinct conformations (Figure 1). In the inactive rest-
ing conformation, the headpiece of the heterodimer bends
towards the plasma membrane, and the transmembrane
domains of the α and β subunits are associated [146]. Upon
ligand binding, the previously bent integrin ectodomain
adopts an activated upright conformation [106, 151]. This
conformational change is conveyed through the transmem-
brane domains towards the cytoplasmic tails [54, 105, 152],
where cytoskeletal proteins and signaling molecules relay the
incomingsignalintracellularly[153].Ininside-outsignaling,
the binding of intracellular molecules, such as talin or
kindlins [154, 155], to the cytoplasmic integrin tails leads via
aseparationofthetransmembranedomains[156]toaswitch
blade-like erection of the extracellular domains [147, 157,
158]. Likewise, in outside-in signaling, ECM ligand binding
to the integrin headpiece also induces a conformational
change in the hybrid domain and thereby a separation of
the integrin subunits’ legs [144]. This parting of the legs
separates the cytosolic tails and allows binding of cytosolic
proteins and thus clustering of integrins and formation of
focal adhesion sites (Figure 1).
By clustering into focal adhesions, integrins recruit talin,
paxillin, α-actinin, tensin, and vinculinandtherebymechan-
ically couple the ECM scaﬀold to the actin cytoskeleton.
Additionally, integrins bind scaﬀolding molecules, such as
p130 CRK/BCAR1, and recruit and activate kinases, such as
focaladhesionkinases(FAKs),Srcfamilykinases(SFKs),and
integrin-linked kinase (ILK), the latter forming a complex
withtheadaptermoleculesparvinandPINCH/LIMS1[159].Journal of Oncology 7
In addition, tetraspanins can recruit integrins to mem-
brane microdomains, thus regulating integrin function
[160]. Thereby, the rather unstable nascent adhesions are
transformed into focal complexes, focal adhesions, ﬁbrillar
adhesions, or podosomes. This clustering of integrins leads
toareorganizationoftheplasmamembranearoundthefocal
adhesion into caveolin-containing lipid rafts, to which also
growth factor receptors often localize, and to the assembly
of adhesion signaling complexes [161–163]. This allows a
regulation of growth factor signals by integrin-mediated
caveolae traﬃcking [164, 165]. In the assembly of such
integrin adhesions, up to 156 distinct molecules, amongst
other adaptor proteins, kinases, and phosphatases, are
involved [48, 163]. Membrane lipid-protein interactions that
modulate the homo- or heterotypic association of receptor
molecules in the cell surface, or between adjacent cells,
have been reviewed recently [166]. From the focal adhesion
sites signal pathways diverge that regulate diverse cellular
programs, such as adhesion, migration, proliferation, and
survival. To provide an overview, integrins generally relay
their signals via the FAK, ERK, and NF-κBp a t h w a y s[ 153].
In most cases, in mechanosensory signaling FAK, Src,
and SH2, domains containing protein tyrosine phosphatase
2( S H P 2 )a r ei n v o l v e d[ 167]. Upon integrin binding, FAK
autophosphorylates and binds to Src, which further phos-
phorylates FAK and several downstream binding partners,
amongst others, JNK and Rho [168–170].
Activated FAK also recruits PI3K, which mediates the
activation of AKT and procures integrin-mediated cell sur-
vival,andlikewisetheantiapoptoticAKTcanbeactivatedvia
Ang-1 [171]. Moreover, signals relayed via integrins and Src
canbeintegratedbyFAKwithgrowthfactorreceptor-relayed
signals via Ras, MEK, and MAPK [172]. Growth factors
can activate Ras signaling independently from integrin-
relayed adhesion signals. Nevertheless, MEK1 and Raf1 are
important interfaces between integrin-relayed and growth-
factor-relayed signaling, because both MEK1 and Raf1 need
to be activated via adhesion-mediated activation of Src and
FAK in order to activate MAPK [173, 174].
An endothelial-speciﬁc ablation of FAK results in im-
paired blood vessel development and embryonic lethality
[175] Downstream of FAK, Src couples integrin-mediated
and VEGF-receptor-mediated proangiogenic signaling in
ECs [176–178]. However, endostatin can also activate Src
via integrin α5β1 and thereby disassemble actin stress ﬁbers
and focal adhesions and thus inhibit cell migration, which is
regulated by integrins via the Ras/ERK pathway [179–181].
Important for adhesion and migration of endothelial and
VSMCs are also p130Cas and PLC-γ, which can interact with
FAK [182–185].
PI3K is of pivotal importance for angiogenesis, because
its deletion results in embryonic lethality E9.5 to E10.5,
when angiogenesis is important for vascular development.
PI3K deletion also causes decreased Tie-2 expression and
thus creates a phenotype resembling Tie-2 deﬁciency [186,
187]. Moreover, EC-speciﬁc deletion of the PI3K isoform
p110α impairs angiogenesis [188]. In ECs, adhesion via
integrins elicits a survival signal via FAK/PI3K/mTOR/4E-
BP1 and Cap-dependent translation [189]. Furthermore,
the activation of PI3K by Ras is important for lymphangio-
genesis [190].
In addition to a direct activation of ERK, integrins can
also activate a Raf/MEK/ERK signaling cascade in ECs [189,
191, 192]. Raf-deﬁcient and MEK-deﬁcient mice have severe
vascular defects [193, 194]. Growth-factor-mediated ERK
signaling is linked with integrin-mediated signaling via FAK
[195]. Integrin-mediated ERK signaling is important for cell
proliferation and migration of ECs [191, 196]. Integrin α1β1
is unique among the collagen-binding integrins because it
promotes cell proliferation by activating the Ras-Shc-MAPK
pathway, and cell cycle progression is regulated via FAK,
Rac, and cyclin D by integrin-mediated adhesion and matrix
stiﬀness [197–199].
Integrins can also activate the NF-κB pathway in ECs and
protectthem fromapoptosis [200–202]. Additionally, NF-κB
signaling regulates the expression of cyclooxgenase-2 (COX-
2), which again is involved in EC spreading and migration
and in the induction of VEGF and FGF-2 [177, 203,
204]. However, inhibition of the NF-κB pathway increases
angiogenesis pathologically [205].
Integrins alone are not oncogenic, but some oncogenes
may depend on integrin signaling for tumor growth and
invasion. For example, integrin-triggered FAK signaling is
essential for Ras- and PI3K-mediated oncogenesis [206,
207]. Also the expression of the cancer stem cell marker
CD44 is integrin-regulated, and it can be speculated that
integrin-relayed signals are needed to maintain a cancer
stem cell population [12, 208]. On the other hand, there
is evidence that the collagen receptor integrin α2β1h a sa
tumor-suppressing function [209, 210].
Ligated integrins promote survival, whereas unligated
integrins recruit caspase-8 to the plasma membrane and
promote apoptosis in a process termed integrin-mediated
death [71, 211], which diﬀers from anoikis induced by loss
of cell adhesion to the ECM [103, 212]. Loss of caspase-8
confers resistance to integrin-mediated death of tumor cells,
and unligated integrin αvβ3 promotes the malignancy of
suchtumors [213,214].Cellsurvivalispromotedbyintegrin
ligation-dependent upregulation of BCL2 and FLIP/CFLAR,
activation of the PI3K-AKT pathway, NF-κB signaling,
and p53 inactivation [176, 202, 215–217]. Survival is also
promoted by crosstalk between integrins and growth factor
receptors,forexample,αvβ3andFGFRorαvβ5andVEGFR2
[195, 218].
In various steps of angiogenesis and tumor progression,
crosstalk between integrins and growth factor receptors
on tumor cells and also on host cells is important. This
crosstalk can consist in either an activation of a latent growth
factor, a regulation of common pathways for signaling or
internalization and recycling, a collaborative or a direct
activation, or also a negative regulation [111]. The outcome
of a growth factor signal in a particular context is often
determined by a synergistic and reciprocal interaction of
integrins with growth factor receptors, such as tyrosine
kinasereceptorslikeVEGFRsandTie-2,Met,andFGFR,and
semaphorins regulate integrin function as well [111, 219–
221]. A complex of VEGF with the ﬁbronectin heparin II
domain increases, upon cell binding via integrin α5β1a n d8 Journal of Oncology
thesignalingviaVEGFR2synergistically[222].Expressionof
integrin α11β1 on tumor-associated ﬁbroblasts has a tumor-
promoting eﬀect, because it upregulates the expression
of insulin-like growth factor 2 (IGF2), which is another
example of integrin-regulated growth factor signaling [223].
Beside binding ECM proteins and thus regulating adhe-
sion and migration, integrins can also directly interact with
pro- and antiangiogenic factors [221]. Integrin α5β1c a n
bind to matrix-bound VEGFR-1 [224]. In addition, integrin
α9β1 can directly interact with VEGF-A, -C, and -D and
also with hepatocyte growth factor (HGF) [113, 114, 225].
Moreover, integrin α3β1a n dαvβ3 bind VEGF-A165 and
VEGF-A189 [112]. FGF is directly bound by integrin αvβ3
[226]. Angiopoietins also can directly interact with many
integrins [115, 221, 227, 228].
In the context of a hypoxic tumor microenvironment, it
is especially interesting that the expression of integrins α1β1
and α2β1 is upregulated by VEGF [51].
3. The DynamicProcess: Connection of
a Tumor to the Host Vasculature
Angiogenesis is an important step in the metastatic cascade,
which not only provides the tumor with nutrients but also
is a route for dissemination. An important trigger for this is
hypoxia [229].
3.1. An Angiogenic Switch Triggers the Angiogenic Cascade. In
avascular tissue regions, an oxygen diﬀusion limit of about
150μm restricts tumor growth to just a few millimeters in
diameter. Thus, in this prevascular phase of tumor dor-
mancy, there is a dynamic equilibrium between proliferation
and hypoxia-induced apoptosis [230]. The dormant phase
ceases when a tumor recruits its own vasculature by the
secretion of angiogenic factors into its environment [231],
a process denoted as angiogenic switch [2, 6]. After this
angiogenic switch is thrown, the tumor hooks up to the
body’s vascular system and thus resumes its growth.
In tumor development, the establishment of an angio-
genic phenotype is a crucial and general step [232–234].
Depending on tumor type and environment, this induction
of new vessel sprouting can occur at diﬀerent stages of
the tumor progression pathway, and it leads to exponential
macroscopic tumor growth [2, 4, 6]. In addition, recent data
indicatethatangiogenesisalsocontributestothemicroscopic
premalignant phase of neoplastic progression [5].
Inﬁltration of bone-marrow-derived monocytes that
diﬀerentiate into macrophages can trigger this angiogenic
switch in spontaneous tumors by releasing both numerous
proangiogenic cytokines, for example, VEGF, TNFα,I L - 8 ,
and bFGF [235, 236] and MMPs (e.g., MMPs-2, -7, and
-9) together with elastase and uPA [236]. These matrix-
degrading enzymes loosen the avascular ECM for the angio-
genic ingrowth of neovessels.
From the multitude of proangiogenic molecules, such as
FGF-1 and -2, G-CSF, HGF, IL-8, PD-ECGF, PGE-1 and -2,
PlGF-1, and -2, TGF-α and -β,T N F - α, and VEGF-A through
E, only the VEGFs and PlGFs are speciﬁc for ECs [230].
VEGF-A, which exists in ﬁve splice variants, is the most
intensively studied one [237]. Mediated by HIF-1, VEGF-A
synergizes with FGF-2. VEGF is upregulated under hypoxic
and hypoglycemic conditions prevailing within tumor tissue
[230].
The role of chemokines in tumor angiogenesis and neo-
vascularization has been reviewed recently [238]. Tumor
cells express CCL2/MCP-1 (C-C-motif ligand 2/mono-
cyte chemotactic protein-1), and thus, tumor-associated
macrophages (TAMs) are recruited, resulting in an inﬂam-
matory response. These TAMs are again a source for
angiogenic growth factors, such as, VEGF and FGF-2 [239,
240]. MCP-1 also mediates the recruitment of mural cells in
an Ang-1-dependent manner in an ex vivo model [241].
Multiple sequential steps are required for angiogenesis
to be successful and in all steps of this angiogenic cascade
integrins, which mediate interactions of cells with surround-
ing insoluble ECM proteins, in addition to soluble growth
factors, play an important role [15]. In a ﬁrst step, the
BM of an existing vessel is degraded by MMPs that are
expressed by ECs, such as MMP-1, MMP-2, MMP-9, and
MT1-MMP/MMP14[242–244],atwhichMMP-9isrequired
for tumor vasculogenesis rather than angiogenesis [245].
Subsequently, cell-matrix contact inﬂuences the outgrowth
of tip cells and the proliferation of stalk cells that thereupon
form endothelial tubes [246]. A new BM is assembled by
newly synthesized BM proteins. Finally, the newly generated
capillaries undergo maturation, pruning, and expansion.
3.2. Tumor Vessels Can Arise by Diﬀerent Types of Vessel
Formation. During embryonic morphogenesis, endothelial
precursor cells called angioblasts initiate the body’s vascu-
lature by forming tubes in a process called vasculogenesis.
This is subsequently accompanied by sprouting (angio-
genesis) of new vessels from already existing ones. Once
morphogenesis is completed, the adult vasculature is largely
quiescent, except for transient events, such as wound healing
or menorrhea [247]. However, angiogenesis takes place
under many pathological conditions, such as atherosclerosis,
endometriosis, osteomyelitis, diabetic retinopathy, rheuma-
toid arthritis, psoriasis, and tumor growth [230]. During
tumor progression, the quiescent vasculature becomes per-
manently activated to sprout new vessels that enable blood
supply and thus help sustain tumor growth [5, 6]. Due to
its increased metabolic rate, tumor tissue requires blood
supply for expansive growth, which is circumstantiated by
the observation that tumor cells, which are p53 deﬁcient
and thus show a reduced apoptosis rate, die beyond an
oxygen diﬀusion limit in the range of 150μm[ 248]. Tumor
cells proliferate around the continuously formed neovessels
which markedly diﬀer from normal vessels in morphology
and molecular composition [219, 249]. Tumor vasculature
generally appears highly tortuous, chaotic, and disorganized.
The vessels themselves are leaky due to a discontinuous
endothelium, a poorly formed BM, and a lack of mural
cells. In addition, tumor cells sometimes mimic ECs. This
poor quality of tumor-associated blood vessels compromises
blood ﬂow, impairs drug delivery, and facilitates tumor
cell intravasation leading to hematogenous or lymphatic
metastasis. In addition to histological vessel malformations,Journal of Oncology 9
tumor vessels show an anomalous composition of their
ECM, for example, tenascin-C and –W, and the oncofetal
ﬁbronectin ED-B splice variants are associated with tumor
vessels [250, 251]. ED-B ﬁbronectin is synthesized by neo-
plastic cells [252]. Melanoma and glioblastoma cells secrete
tenascin-C as do cancer-associated ﬁbroblasts (CAF) of
most carcinomas [253]. Tenascin-C stimulates angiogenesis
in ECs, mediates survival of tumor stem cells, enhances
proliferation,invasiveness,andmetastasisintumorcells,and
blocks immunosurveillance [250, 253]. Tenascin-W is more
strictly associated with tumorigenesis and can be used as
a tumor biomarker for breast and colon cancer, because it
is undetectable in healthy stroma but overexpressed in the
tumor stroma [254, 255].
Vascularization mechanisms in cancer have been re-
viewed recently [256, 257]. New tumor blood vessels can
either arise by vessel co-option or be formed by tumor
angiogenesis, but there is also evidence for vasculogenesis or
recruitment of circulating bone-marrow-derived endothelial
progenitor cells that diﬀerentiate into ECs [230, 258–260]
(Figure 2(A)). Depending on the tumor type, tumor blood
vessels build diﬀerent and characteristic vascular beds,
and, according to the function of the vascular bed and
the osmotic pressure of the surrounding tissue, endothelia
represent highly heterogeneous “vascular addresses” [230].
Tumor vessels constantly change their shape due to persis-
tent growth, and about 30% of the vasculature comprise
arteriovenous shunts bypassing capillaries. The concomitant
poor perfusion leads to hypoxia of ECs, which consequently
synthesize more proangiogenic molecules and thus crank
tumor angiogenesis [230].
3.2.1. Endothelial Sprouting. Endothelial sprouting can be
triggered by hypoxia, hypoglycemia, and inﬂammatory or
mechanical stimuli, such as blood pressure, and is regulated
by many angiogenic growth factors, such as VEGF, and
matrix proteases. When neovessels sprout from capillaries,
pericytes are selectively lost, and upon receiving an angio-
genic stimulus, select ECs diﬀerentiate into tip cells that
invade the avascular ECM (Figure 2(B)). These tip cells
migrate into the ECM following the stimulatory gradient.
Behind the tip cells, other ECs begin to proliferate and,
as stalk cells, form cord-like structures. These develop
into endothelial tubes [130, 261, 262] that subsequently
anastomose and thus allow blood ﬂow. Finally, pericytes and
smooth muscle cells are recruited, a new BM is synthesized,
and the ECs become quiescent again.
The molecular background of capillary sprouting and
the key role of VEGF have been reviewed by Carmeliet
[231]. Upon a hypoxic stimulus, VEGF is produced, and as
a consequence the endothelium’s permeability is increased
and the BM loosened by the activity of MMPs [243, 263]
and the urokinase plasminogen activator system [264]. The
MMP inducer EMMPRIN/CD147 also upregulates soluble
VEGF isoforms 121 and 165 and VEGFR-2 on ECs and
thus promotes sprouting angiogenesis [265]. Integrin αvβ3
mediates migration into the ﬁbrin-rich cancer stroma and
furthermore can associate with MMP-2, thus enabling ECs
to maintain the BM in the sol state and to promote tumor
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Figure 2: Diverse types of vessel formation. Tumor neovasculariza-
tion can take place by distinct types of vessel formation, which can
proceed simultaneously and also merge seamlessly. (A) Neovessel
formation by recruitment of bone-marrow-derived endothelial
progenitor cells. (B) Sprouting angiogenesis is initiated by the
diﬀerentiation of an EC into a migratory but nonproliferating tip
cell. (C) Intussusceptive angiogenesis starts with the insertion of a
connectivetissuepillarintoapreexistingvessel,andthevesselisdis-
placedasthepillarextendsinsize.(D)Inglomeruloidangiogenesis,
complex vascular aggregates of several closely associated vessels are
formed. (E) Vessel co-option is the acquisition of host capillaries by
the tumor. (F) In vascular mimicry, tumor cells can partly assume
EC function and form vessel-like hollow structures. Arrows denote
consecutivestagesofvesselformation.Tumortissueisdepicteddark
gray. See text for details.
cell invasion [266]. In addition to VEGF, FGF, PDGF, and
PlDGF are involved, and Ang-2/Tie-2 signaling regulates the
detachment of pericytes. Later, PDGF-BB recruits pericytes
a n ds m o o t hm u s c l ec e l l st ot h en e w l yf o r m e dE Ct u b e ,
and TGF-β1 and Ang-1/Tie-2 stabilize the EC-mural cell
interaction [231].
3.2.2. Intussusceptive Angiogenesis. Another way of tumor
neovascularization is intussusceptive angiogenesis, which
represents a nonproliferative and noninvasive mechanism
for the enlargement of a capillary plexus by intussusceptive
growth, arborization, and remodeling [267]( Figure 2(C)).
As this mode of vascularization is mostly independent from
EC proliferation and migration, as well as BM degradation,
this process is more economical and, occurring within
hours or even minutes, is noticeably faster than sprouting10 Journal of Oncology
angiogenesis [268]. It begins with the formation of translu-
minal pillars from the EC walls. Their subsequent expansion
splits the preexisting vessel into two, thereby enhancing the
vascular surface. In a subsequent process of arborization,
the disorganized capillary network is remodeled into a
functional tree-like structure by serial pillar formation. In
a ﬁnal remodeling step, the branching angles are modiﬁed,
and the capillary network is pruned. The formation of new
capillaries is initiated by sprouting angiogenesis that is later
accompanied or followed by intussusceptive angiogenesis,
which increases the EC surface [269]. Intussusceptive angio-
genesis is synergistically regulated by VEGF and Ang-1,
and it seems to be induced by laminar shear stress on the
vessel walls, whereas oscillating shear stress favors sprouting
angiogenesis [269].
3.2.3. Glomeruloid Angiogenesis. In many aggressive tumors,
glomeruloid angiogenesis gives rise to complex vascular
structures termed glomeruloid bodies, in which several
microvessels together are ensheathed by a BM of varying
thickness containing sparse pericytes [270]( Figure 2(D)).
The frequency of occurrence of such glomeruloid bodies
is an indication for the tumor’s aggressiveness and the
patient’s survival [271]. The formation of such glomeruloid
bodiesisratheraremodelingthantrueangiogenesis,because
proliferating and migrating tumor cells can actively pull
capillaries of the surrounding host vasculature and adjacent
capillary branching points into the tumor node. Thereby,
formed coiled vascular structures develop subsequently into
glomeruloid bodies that are connected to the surrounding
vasculature via numerous narrowed capillaries [256].
3.2.4. Vessel Co-Option. Malignant cells can initially grow
in the vicinity and along pre-existing microvessels and thus
use the host vasculature for their own beneﬁt (Figure 2(E)).
Thisco-optionofthehostvasculaturewasoriginallybelieved
to be limited to the initial phase of tumorigenesis [272].
Meanwhile, however, there is evidence that vessel co-option
might persist during all stages of primary and metastatic
growth of various tumors [256], for example, cutaneous
melanoma, which appears to grow by co-opting the vascular
plexus in its surrounding connective tissue, while there is no
sign of directed vessel ingrowth [273].
Vessel co-option is regulated dependent on the tumor
type and the host environment, but the key regulators are
again VEGF and angiopoietins [272, 274]. Ang-1 binds to
Tie-2 and thus triggers signaling cascades, assuring survival
and quiescence of ECs, and thus causing tumor vessel
maintenance, whereas the nonsignaling Tie-2 ligand Ang-2
actsasanegativeregulatoranddestabilizesthecapillarywalls
by detachment of pericytes [272, 274]. Subsequently, VEGF
via its receptor VEGFR-2 promotes both survival of ECs and
growth of new vessels [237, 275].
3.2.5. Vascular Mimicry. Aggressive melanomas can form
ﬂuid-ﬁlled vessel-like channels without any EC lining in
a nonangiogenic process termed vascular mimicry [276]
(Figure 2(F)). These channels allow perfusion independent
of angiogenesis, and they can arise by two types of vascu-
logenic mimicry, designated the tubular and the patterned
matrix type [277]. These tubular vessel-like networks resem-
ble the pattern of embryonic vascular networks, and, in
their gene expression pattern, aggressive tumors that form
such channels resemble endothelial, pericytes, and other
precursor stem cells, suggesting that tumor cells might
disguise as embryonic stem-cell-like or other cell types
[256]. Vasculogenic mimicry of the patterned matrix type
looks completely diﬀerent and is characterized by a ﬂuid-
conductingmeshworkofextravascularpatterneddepositions
of matrix proteins such as laminins, collagens IV and VI, and
heparin sulfate proteoglycans that anastomose with blood
vessels [277–279]. Although it is not yet elucidated how such
channels are connected to the vasculature, the latter type
of vascular mimicry has been reported for many cancers,
such as breast, ovarian, and prostate carcinoma, melanoma,
soft tissue sarcomas, osteosarcoma, and phaeochromocy-
toma [277, 280]. In aggressive melanoma, the expression
of tissue factor pathway-associated genes, such as tissue
factor (TF), TF pathway inhibitor-1 (TFPI-1), and TFPI-
2, is upregulated, suggesting an anticoagulation mechanism
in the channel-forming tumor cells [281]. Fluid propelled
throughthesechannelsbyapressuregradientmightfacilitate
the supply with nutrients and oxygen, and, additionally, this
ﬂuid-conducting network could substitute for a lymphatic
vascular system and drain extravasated interstitial ﬂuid
in tumors that lack lymphatic vessels, for example, uveal
melanoma [279, 280].
4. Manipulation of Cell Matrix Interactionin
Tumor Angiogenesis
Cell-matrix interactions regulate signaling pathways that are
intricately interconnected with cytokine-regulated pathways,
which complicates the analysis of their contribution to a
particular step in angiogenesis [153]. ECM receptors can
be manipulated with a wide variety of diﬀerent compounds
ranging from endogenous compounds, such as matrikines,
over their synthetic analogues and peptides mimicking only
integrin-binding sites to function-blocking antibodies and
small molecules with integrin inhibitory function. Other
starting points for an antiangiogenic therapy are the inhibi-
tion of signaling cascades downstream of the ECM receptors
or cytokine receptors and as a new avenue the blocking
of microRNAs with antisense RNAs in ECs [282, 283]. An
eﬃcient antivascular cancer therapy can target either the
angiogenic signaling pathways or the vascularization mech-
anism [256]. A combination of conventional chemotherapy
with angiosuppressive or vascular disrupting therapy is often
problematic and needs careful design [256].
4.1. Pharmacological Intervention of Integrin-ECM Interac-
tion. In addition to soluble growth factors, such as VEGF,
there are several endogenous angiogenesis inhibitors, for
example, endostatin, endorepellin, and tumstatin, which
share the common feature that they all are proteolytic frag-
ments of ECM molecules [284, 285]. In tumor angiogenesisJournal of Oncology 11
within a primary tumor, such ECM fragments are generated
by the release of MMPs, in order to degrade the BM. This
results not only in labile and leaky tumor vessels but at
the same time keeps metastases from growing, as these
endogenous angiogenesis inhibitors are distributed via the
blood stream [230]. Therefore, they are of pharmacological
interest with regard to their use as angiogenesis inhibitors.
Intensive eﬀortshavebeendirectedtowardsthedevelopment
of integrin antagonists for the treatment of cancer and many
other diseases, ranging from autoimmune diseases over
inﬂammatory to thrombotic diseases, and their applications
seem promising [11, 286]. Integrin-mediated interactions
of cells with their surrounding ECM can be manipulated
by antibodies, peptides, small nonpeptidic compounds, and
endogenous inhibitors (Figure 3). Integrin antagonists with
antiangiogenic activities have been reviewed recently with
special emphasis on drugs that are in clinical trials [11].
Spurred by the success in pharmacologically targeting
RGD-dependent integrins, there are also attempts to phar-
macologically manipulate RGD-independent integrins, such
as the collagen- and laminin-binding integrins, as reviewed
recently [287]. The collagen-binding subgroup of integrins
with their common A domain comprises interesting targets
in the development of drugs against thrombosis, inﬂam-
matory diseases, and cancer. TSPs-1 and -2 are naturally
occurring potent angiogenesis inhibitors, and their anti-
angiogenic eﬀects can be imitated by short-peptide mimetics
that among other targets bind to β1 integrins [288, 289].
An endogenous inhibitor, which blocks the interaction
of integrin α1β1 with collagen I and also binds to heparan
sulfate proteoglycans, is arresten, the C-terminal fragment
of the collagen IV α1 chain [290, 291]. Endorepellin, a
C-terminal fragment of perlecan speciﬁcally blocks the
function of integrin α2β1[ 292] and interestingly also
binds to endostatin, thus counteracting its antiangiogenic
eﬀect [293]. Additionally, integrin α1β1 can be speciﬁcally
inhibited with obtustatin from the snake venom of Vipera
lebetina obtusa [294, 295]. The interaction of integrin α2β1
with collagen can be speciﬁcally inhibited with the C-
type lectin rhodocetin from the snake venom of Callose-
lasma rhodostoma [296, 297]. In addition, it can also be
selectively antagonized by the protein angiocidin, which
was ﬁrst detected in lung carcinoma cells [298, 299]. The
aromatic tetracyclic polyketides maggiemycin and anhydro-
maggiemycin from Streptomyces, which have been described
as potential antitumor agents [300], inhibit collagen binding
by blocking the A domain of the integrin subunits α1,
α2, α11, and to a lesser extent α10 while cell adhesion
to ﬁbronectin, mediated by integrins α5β1, αvβ3, αvβ5,
is unaﬀected [301]. Recently, the sulfonamide derivative
BTT-3016 has been described as a potent antithrombotic
small-molecule inhibitor of integrin α2β1 with only slight
eﬀect on other collagen-binding integrins and no eﬀect on
ﬁbronectin- or vitronectin-binding integrins [302]. Another
sulfonamide derivative, E7820, which does not interfere with
integrin-ligand interaction, reduces integrin α2 expression
onthemRNAlevel[303].Angiogenesiscanbeinhibitedwith
antibodies against the α subunits of the integrins α1β1a n d
α2β1, whereas quiescent vessels are not aﬀected [230].
In a phase I clinical trial, endostatin, the C-terminal
fragment of collagen XVIII, blocks the function of integrin
α5β1[ 179, 304, 305] and also binds to heparin and with
lower aﬃnities to other heparan sulfate proteoglycans that
are involved in growth factor signaling [306, 307]. Endo-
statin’s antiangiogenic activity can also be mimicked with
derived short non-RGD but arginine-rich peptides [308].
Integrin α5β1 can also be blocked by the synthetic non-
RGD peptides PHSCN, named ATN-161, [309] and cyclic
CRRETAWAC[310],aswellasbythepeptidemimeticsSJ749
[311] and JSM6427 [312], and it can be inhibited by the
aﬃnity-matured humanized chimeric monoclonal antibody
M200/volociximab [313].
Angiostatinisaproteolyticfragmentofplasminogenthat
eﬀectively inhibits integrin αvβ3[ 314], and its antiangio-
genic eﬀect can also be achieved by its isolated kringle-5
domain [315]. Kringle-1 to 3 show the same antiproliferative
eﬀect as the whole angiostatin, but hardly inhibit migration,
whereas kringle-4 inhibits EC migration but shows only a
marginal antiproliferative eﬀect [316]. Other endogenous
integrin αvβ3 inhibitors are the collagen XVIII fragment
endostatin [304], and the C-terminal fragment of the
collagen IV α3-chain termed tumstatin [317], which also
binds to integrin α6β1[ 318]. Tumstatin has two binding
sites for integrin αvβ3. The N-terminal site mediates an
antiangiogenic signal, whereas the C-terminal binding site
is associated with the antitumor cellactivity [318, 319].
Canstatin, the NC1 domain of the collagen IV α2 chain,
inhibits both integrins αvβ3a n dαvβ5[ 320] and seems
to interact with integrin α3β1t o o[ 321]. A hemopexin-
like domain comprising C-terminal fragment of MMP-2,
termed PEX, also antagonizes integrin αvβ3 by preventing
its binding to MMP-2 and thus inhibiting proteolytic activity
on the cell surface, especially during vessel maturation [322,
323]. Fastatin and other FAS1 domains, which are present
in the four human proteins periostin, FEEL1, FEEL2, and
βhig-h3, also function via integrin αvβ3a se n d o g e n o u s
regulators of pathogenic angiogenesis [324]. Next to these
natural antagonists there is a variety of synthetic RGD—
containing peptide inhibitors that mimic a motif that occurs
on many ECM molecules, such as ﬁbronectin, vitronectin,
ﬁbrinogen, osteopontin, TSP, vWF, and partially degraded
collagen.Mostintegrinsoftheαvsubfamilyandtheintegrins
α5β1a n dαIIbβ3 bind to this motif. Therefore, adhesion and
spreading of ECs to the ECM can be competitively inhib-
ited by RGD peptides, whereby anchorage-dependent ECs
undergo apoptosis [230]. To this group belong compounds,
such as cilengitide/EMD121974 [325], S137 and S247 [326,
327], the TSP-derived peptide TP508/chrysalin [328], and
several integrin αvβ3- and αvβ5-speciﬁc peptidomimetics,
such as BCH-14661, which preferentially inhibits αvβ3a n d
BCH-15046, which blocks αvβ3, αvβ5, and α5β1[ 329],
SCH221153 [330], and ST1646 [331]. Another inhibitor
is the non-peptide antibiotic thiolutin, which intracellu-
larly blocks paxillin and thus, indirectly, integrin αvβ3-
mediated adhesion to vitronectin [332]. Antibodies against
the β3 subunit inhibit contact of ECs to vitronectin and
concomitantly VEGF-induced tyrosine phosphorylation of
VEGFR-2 in cell culture studies [333]. Moreover, integrin12 Journal of Oncology
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Figure 3: Options to manipulate integrin function. Essential cellular functions, such as adhesion, migration, proliferation, and survival,
which all are regulated by integrins, can pharmacologically be manipulated with a panoply of matrikines, antibodies, peptides, and small
molecule inhibitors, many of which are used as therapeutic tools in combination with conventional chemo- or radiotherapy to attack tumor
cells and vasculature. Details are described in the text.
αvβ3c a nb ee ﬀectively antagonized with the monoclonal
antibody LM609/MEDI-552 and its humanized derivative
abegrin/etaracizumab/vitaxin [57, 334–337]. In contrast,
the humanized anti-αv antibody CNTO95 targets both
integrinsαvβ3andαvβ5[338].ThehumanizedFabfragment
17E6/abciximab/ReoPro of the monoclonal antibody c7E3
inhibits the integrins αvβ3 and also αMβ2/Mac-1 [339,
340], whereas the human-speciﬁc monoclonal antibody
17E6 targets all αv integrins [341]. Currently, humanized or
chimeric integrin antibody antagonists of αvβ3, αvβ5, and
α5β1, and peptide inhibitors of these integrins are in clinical
trials as antiangiogenic agents [180].
5. Applicationsand Outlook
Integrins and their binding partners are of special interest
as potential therapeutic targets, and several are already in
clinical trials. However, the results fall short of the initial
expectations, pointing out that monotherapy with a single
angiogenesis inhibitor is not suﬃcient to counteract the
numerous angiogenic factors involved in tumor progres-
sion [231]. Moreover, there are some caveats in aiming
at integrins as therapeutic targets. Obviously, integrins
are expressed on virtually all cells under physiological as
well as pathological conditions, and it is a major chal-
lenge to target exclusively integrins on tumor or tumor-
associated cells. Another problem is that low concentrations
of antagonists alter the signaling of integrins and other
receptors. When administered in nanomolar concentrations,
the RGD-containing inhibitors cilengitide and S 36578 alter
the traﬃcking of integrins and VEGFR2 in tumor ECs, thus
stimulating angiogenesis and tumor growth [342].
Currenttumortherapyaimsatvesseleradicationinorder
to disrupt the connection of the tumor to the vascular
system and thus cut oﬀ the supply of nutrients and oxygen.
This can be done with compounds that preferentially aﬀect
tumorendothelia ratherthannormalcells,thatis,(i)speciﬁc
angiogenesis inhibitors, (ii) tumor vessel toxins that attack
inherent weaknesses in static tumor vessel endothelia and
associated vascular structures, and (iii) dual-action com-
pounds [343]. However, within the last years, a paradigm
shift has taken place [344, 345]. Vessel normalization by
pruning immature vessels and increasing pericytes and
BM coverage of the remaining vessels comes to the fore,
rather than vessel eradication, because mere antiangiogenic
treatment can worsen malignancy [346]. A malformed
tumor vasculature creates and aggravates a hypoxic and
acidic milieu which hampers drug delivery and perfusion
[347–349], and, due to its leaky endothelium, it promotes
tumor cell dissemination [346]. Therefore, chemotherapeu-
tic eﬃcacy can be ameliorated by a concomitant vessel
normalization therapy which improves delivery and eﬃcacy
of cytotoxic drugs and also sensitizes the tumor cells to
radiation [345, 350].
In vessel normalization, the interaction of cells with
their surrounding ECM via integrins is of special impor-
tance.However,manyantiangiogenic compounds, forexam-
ple, ATN-161, endostatin, and integrin inhibitors, showJournal of Oncology 13
hormetic, that is, bell- or U-shaped, dose-response curves
and thus present a challenge for clinical translation [351].
Nanomolar concentrations of RGD-mimetic αvβ3a n dαvβ5
inhibitors (S 36578 and cilengitide) can paradoxically
stimulate tumor growth and angiogenesis by altering the
traﬃcking of αvβ3 integrin and VEGFR2. Thus, they
promote the migration of ECs towards VEGF, which has
important implications for the use of RGD mimetics in
tumor therapy [342]. Thus, depending on tumor type, dose,
and manner of application, the currently available-integrin
targeting compounds can act either anti- or proangiogenic.
A promising approach may be a combination therapy that
blocks simultaneously angiogenic integrin αvβ3 and VEGFR
activities [352–355].
To circumvent these problems, instead of targeting the
integrins, which are in principle present on both normal and
malignant cells, another strategy aims at tumor-promoting
integrin ligands, such as ED-B ﬁbronectin, tenascin-C, and
tenascin W [252, 253, 255]. Invasive tumor cells partially
degrade and denature their surrounding ECM, and the
thereby released cryptic collagen IV epitope HU177 may also
be a potential target for antiangiogenic and tumor-selective
drug delivery [356].
In comparison to a systemic administration of a chemo-
therapeutic agent, its therapeutic index can be increased
by selectively targeting integrins that are overexpressed on
tumor cells [357]. Chemotherapeutic small molecules, pep-
tides, and proteins as well as nanoparticle-carried chemo-
therapeutics, which are conjugated to ligands of integrins
that are overexpressed on angiogenic ECs or tumor cells, can
be selectively internalized after integrin binding [357]. Espe-
cially nanoparticles, such as micelles, liposomes, polymeric
nanospheres, and polymersomes loaded with chemothera-
peutic or radiotherapeutic drugs and equipped with multi-
valent integrin ligands show decreased systemic toxicity, pro-
longed half-life and passive retention in the tumor, improved
bindingaﬃnity,andfacilitatedinternalization,thusresulting
in increased drug delivery [12, 357, 358]. A therapeutic
strategy that targets several integrins and receptors by such
chemo-, radio-, and possibly gene therapeutic approaches
m a yb em o r ee ﬀective than a monotherapy [231, 357].
Coadministration of the αv integrin-targeting cyclic pep-
tide iRGD (CRGDKGPDC), or structurally closely related
peptides, with anticancer drugs considerably enhances their
eﬃcacy and selectivity [359]. Upon binding to αv integrin-
expressing tumor ECs, iRGD is proteolytically processed to
CRDGK with a much weaker integrin aﬃnity, whereas this
truncated peptide shows an increased aﬃnity to neuropilin-
1 (NRP-1), thus increasing vascular and tissue perme-
ability in a tumor-speciﬁc and NRP-1-dependent manner
[359]. Interestingly, this coadministration does not require
chemical conjugation of the drug with the iRGD peptide;
that is, approved drugs could be used unmodiﬁed [359].
Coadministration of such a tumor-penetrating peptide with
either small molecules, such as doxorubicin, antibodies, such
as trastuzumab, or nanoparticles, such as Nab-paclitaxel
(abraxane) or doxorubicin-loaded liposomes, resulted in
equivalentorincreaseddeliveryandeﬃcacy,anditimproved
their therapeutic index by lowering the eﬀective dose [359].
Additionally, integrins can be used as biomarkers to non-
invasively assess the eﬃcacy of chemotherapeutic and radio-
therapeutic drugs [12]. Integrin-targeted probes can be
used to visualize tumor angiogenesis and the response to
chemo- and radiotherapy by various imaging methods,
such as magnetic resonance imaging (MRI), positron emis-
sion tomography (PET), and ultrasonography [360–362].
Moreover, ﬂuorescence labeling of integrin ligands allows
intraoperative ﬂuorescence imaging, thus providing a tool
to intraoperatively detect and remove metastases of sub-
millimeter size [363].
In summary, the above data illustrate the importance
of integrins and integrin-binding and signaling proteins in
both physiological and pathological blood vessel formation.
Thus, they may be potential targets for antiangiogenic tumor
therapy. Although our knowledge concerning this matter has
increasedremarkablywithinthelastyears,theunderstanding
is far from complete.
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